TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01442077

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)
Description: Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
Study: NCT00668330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate+alfacalcidol+calcium
Description: Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate+alfacalcidol+calcium
Description: Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo ibandronate+alfacalcidol+calcium
Description: placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo ibandronate+alfacalcidol+calcium
Description: placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
Study: NCT02867111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sperm Selection Assay
Description: Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sperm Selection Assay
Description: Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attractant Substance
Description: Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: An in vitro fertilization procedure in which a single sperm is injected directly into an egg

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ICSI
Description: An in vitro fertilization procedure in which a single sperm is injected directly into an egg

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ICSI
Description: An in vitro fertilization procedure in which a single sperm is injected directly into an egg
Study: NCT02533349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motilitone
Description: 30mg, 1 tablet, 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: 40mg, 1 tablet, 1time a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40mg, 1 tablet, 1time a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30mg, 1 tablet, 3 times a day
Study: NCT01347268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist administration and continued low dose r-FSH 75 IU

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: withdrawing GnRH agonists
Description: withdrawing GnRH agonists and continued low dose r-FSH 75 IU
Study: NCT00197119

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix™ Adult
Description: Intramuscular administration in the deltoid region (2 doses).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix™ Junior
Description: Intramuscular administration in the deltoid region (3 doses).
Study: NCT04174222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate NMB
Description: Neuromuscular block was maintained at train of four count 1-2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep NMB
Description: Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
Study: NCT01245803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: additional rosuvastatin loading
Description: additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: sugar pill is given 18-24hr and 4-6hr before PCI as control
Study: NCT02861625

Intervention type: BEHAVIORAL
Intervention: Letter of condolence and post-death medical consultation
Description: Process of sending a letter of condolence with consultation proposition.
Study: NCT04598945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionel MRI
Description: During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionel MRI
Description: During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
Study: NCT00333502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Description: Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
Study: NCT00035802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
Study: NCT00821119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal intermittent positive pressure ventilation
Description: Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal intermittent positive pressure ventilation
Description: Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
Study: NCT00685425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI
Description: 1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol
Description: 1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI
Study: NCT01562587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: A single bolus dose is administered. Injected intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
Study: NCT02625129

Intervention type: OTHER
Intervention: Pharmacist-provided travel care
Description: Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
Study: NCT03361618

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
Study: NCT02041221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1316 Dose 1
Description: The subjects will receive SPARC1316.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1316 Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1316 Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1316 Dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1316 Dose 5
Study: NCT03284125

Intervention type: OTHER
Intervention: Swallowing disorders evaluation
Description: Self-administered questionnaires and non-invasive clinics tests
Study: NCT03790449

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control Programme
Description: The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Programme
Description: The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
Study: NCT03442374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
Study: NCT03320642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally once daily at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor
Description: The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
Study: NCT04115371

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention
Description: Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
Study: NCT01549249

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: optical coherence tomography
Description: spectral-domain optical coherence tomography
Study: NCT01508832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Digital Nerve Block
Description: Lidocaine 1% Digital Nerve Block (2 cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Digital Block
Description: Bupivacaine 0.25% Digital Block (2 cc)
Study: NCT01154465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central Venous Catheter Insertion
Description: The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central Venous Catheter Insertion
Description: The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method.
Study: NCT01626729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traffic Light
Description: A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traffic Light+
Description: A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facts Up Front
Description: A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facts Up Front+
Description: A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No label control group
Description: No label control group
Study: NCT00334139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: every 4 weeks for 4 months
Study: NCT00344539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel®
Description: AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel®
Description: AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel®
Description: AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
Study: NCT04169438

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream Base Emulsion Moisturizer + Petrolatum
Description: Topical vehicle white (bone) color, oil/water emulsion moisturizer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FS2 Emulsion Moisturizer + Petrolatum
Description: Topical FS2 white (bone) color, oil/water emulsion moisturizer.
Study: NCT00344539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Description: CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Description: CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
Study: NCT01565252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: eggs enriched Omega-3
Description: In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
Study: NCT02253745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match V81444 twice daily for 13 days and once on Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match V81444 twice daily for 13 days and once on Day 14
Study: NCT02241278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
Study: NCT00610818

Intervention type: OTHER
Intervention: Palifermin
Description: day -14, -13, -12 before transplant and then day 0,1,2 after transplant
Study: NCT01648985

Intervention type: OTHER
Intervention: Diabetes in stroke/TIA
Description: Mostly no intervention. A small Group of the patients recieved Yoga